217 related articles for article (PubMed ID: 29907650)
21. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE; Frank DA
Mol Cancer Ther; 2014 May; 13(5):1194-205. PubMed ID: 24435449
[TBL] [Abstract][Full Text] [Related]
22. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
[TBL] [Abstract][Full Text] [Related]
23. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
[TBL] [Abstract][Full Text] [Related]
24. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
Mullighan CG; Collins-Underwood JR; Phillips LA; Loudin MG; Liu W; Zhang J; Ma J; Coustan-Smith E; Harvey RC; Willman CL; Mikhail FM; Meyer J; Carroll AJ; Williams RT; Cheng J; Heerema NA; Basso G; Pession A; Pui CH; Raimondi SC; Hunger SP; Downing JR; Carroll WL; Rabin KR
Nat Genet; 2009 Nov; 41(11):1243-6. PubMed ID: 19838194
[TBL] [Abstract][Full Text] [Related]
25. RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia.
Koschut D; Ray D; Li Z; Giarin E; Groet J; Alić I; Kham SK; Chng WJ; Ariffin H; Weinstock DM; Yeoh AE; Basso G; Nižetić D
Oncogene; 2021 Jan; 40(4):746-762. PubMed ID: 33247204
[TBL] [Abstract][Full Text] [Related]
26. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
27. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
Jain N; Roberts KG; Jabbour E; Patel K; Eterovic AK; Chen K; Zweidler-McKay P; Lu X; Fawcett G; Wang SA; Konoplev S; Harvey RC; Chen IM; Payne-Turner D; Valentine M; Thomas D; Garcia-Manero G; Ravandi F; Cortes J; Kornblau S; O'Brien S; Pierce S; Jorgensen J; Shaw KR; Willman CL; Mullighan CG; Kantarjian H; Konopleva M
Blood; 2017 Feb; 129(5):572-581. PubMed ID: 27919910
[TBL] [Abstract][Full Text] [Related]
28. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.
Sadras T; Heatley SL; Kok CH; McClure BJ; Yeung D; Hughes TP; Sutton R; Ziegler DS; White DL
Cancer Genet; 2017 Oct; 216-217():86-90. PubMed ID: 29025600
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
[TBL] [Abstract][Full Text] [Related]
31. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
[TBL] [Abstract][Full Text] [Related]
32. Targeting signaling pathways in acute lymphoblastic leukemia: new insights.
Harrison CJ
Hematology Am Soc Hematol Educ Program; 2013; 2013():118-25. PubMed ID: 24319172
[TBL] [Abstract][Full Text] [Related]
33. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.
Tasian SK; Loh ML
Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304
[TBL] [Abstract][Full Text] [Related]
34. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.
Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194
[TBL] [Abstract][Full Text] [Related]
35. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR
Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663
[TBL] [Abstract][Full Text] [Related]
36. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
[No Abstract] [Full Text] [Related]
38. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
39. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
Malinge S; Ben-Abdelali R; Settegrana C; Radford-Weiss I; Debre M; Beldjord K; Macintyre EA; Villeval JL; Vainchenker W; Berger R; Bernard OA; Delabesse E; Penard-Lacronique V
Blood; 2007 Mar; 109(5):2202-4. PubMed ID: 17068151
[TBL] [Abstract][Full Text] [Related]
40. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
